Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Nawwar Al-Attar
The decision to operate results from a balance that can be delicate between the risk and the outcome benefit expected from surgical intervention. The physician may believe that it is too late to refer a patient for surgical intervention due to advanced age, in the presence of significant and serious co-morbidities, or/and when myocardial contractile reserve is poor. The surgeon, on his/her end, may be reluctant to perform the intervention in the presence of technical challenges.
The natural history of aortic stenosis (AS) has shown that in the absence of surgical management, patients will develop progressively invalidating symptoms of syncope and angina. Mortality rates from congestive heart failure at 5 and 10 years are 68% and 82% respectively (1). Indication for surgery rises when the severity of the stenosis becomes significant (valve area <1cm² or 0.6 cm²/m² body surface area) or the patient becomes symptomatic (2). Conventional surgical AVR is a reference treatment and is performed under cardiopulmonary bypass, cardiac arrest and aortic cross-clamping. Isolated AVR carries an average 30-day mortality rate of 3.8±1.5% (3). It is the “gold standard” for symptomatic aortic stenosis and has been shown to improve outcome and survival. Intervention indications have been revised to performing corrective procedures before establishing severe myocardial damage and even prior to onset of symptoms (4). A multivariate analysis of almost 6,000 patients having AVR, showed that the 5 most important predictors of mortality were age ≥ 80 years, NYHA class ≥ III, EF ≤ 30% associated with previous MI, emergent AVR and concomitant coronary artery bypass graft (CABG) surgery (5).
Cardiologists are reluctant to refer elderly and high-risk patients for AVR. Age was a recurrent factor for refusing surgery in 31.8% of patients with AS from the Euro Heart Survey on Valvular Heart Disease (6) and 62% of patients with AS in another study from the USA (7). It is an important predictor of operative risk and survival in cardiac surgery. Advanced age has repeatedly and consistently been shown to be a predictor of both poor in-hospital outcome and long term survival. In a series of 6,359 patients undergoing aortic valve replacement, Hannan et al showed an incremental increase in the adjusted hazard ratio for 30-month survival from 1.57 to 2.18 to 3.96 in age ranges 65-74 y, 75-84 y and ≥85 y, respectively. After isolated AVR, the 30-month survival was 90.1% for patients age under 75 and 86.2% for patients >75 years of age (8). A study in octogenarians with severe AS showed that AVR had significant survival benefit with 1-year, 2-year and 5-year survival rates of 87, 78 and 68%, respectively, compared with 52, 40 and 22%, respectively, in those who received no AVR (9). Elderly patients on the other hand experience increased operative mortality and also are at higher risk for valve-related events (10,11). Nevertheless, according to published guidelines, age is not, per se, a contraindication to AVR (12,13,14). Analysis of determinants of operative mortality in relation to age showed that age is not linearly related to mortality rates after AVR (15) and that there is considerable functional improvement that follows valve replacement (16).
Patients can be refused for surgery because of severe comorbidities known to be associated with poor outcome. Comorbidities may be related to concomitant cardiac diseases which can further compromise myocardial function such as poor left ventricular ejection fraction (LVEF), previous cardiac surgery, and associated coronary artery disease (CAD). Other comorbidities relating to the general condition of the patient, such as neurological dysfunction, chronic lung disease, liver cirrhosis and renal insufficiency are additional predictors of poor outcome. These patients are prone to severe postoperative complications such as infections and bleeding; and the procedure itself may further compromise vital organ function (17,18). The contribution of these factors can increase the odds ratio for operative mortality by a factor of 10.6 for emergency versus elective surgery, 4.9 for renal failure, 3.1 for NYHA class (III-IV versus I-II) and 4.3 for neurological dysfunction. Thus, it may be too late to perform elective valve replacement on patients with terminal end-organ failure of the liver (Child-Pugh class B or C cirrhosis) or lung.
CAD especially may negatively affect prognosis in patients with AS due to the presence of a concomitant cardiac pathology and impaired LV function from an ischaemic myocardium. Patients with acute myocardial infarction (AMI) <24 hours or who were haemodynamically unstable had a risk-adjusted 30-month survival of 59.6%, compared with 83.6% for patients with neither AMI <24 hours nor haemodynamic instability. The operative mortality of AVR doubles with the addition of a concomitant CABG procedure, a figure that cannot be explained solely by the simple increment in time from cross clamping and cardiopulmonary bypass. Concomitant CABG had an adjusted 30-month mortality hazard ratio of 1.26 in comparison with isolated AVR. After AVR, LV dimensions normalises more quickly in the group with isolated AVR compared to those with concomitant CABG, further suggesting that CAD has a negative impact on postoperative myocardial recovery. The operative risk in patients with CAD requiring concomitant CABG is further compounded by a significantly higher prevalence of cerebrovascular disease, peripheral vascular disease, extensive aortic atherosclerosis, diabetes and renal failure. Nevertheless, there is a consensus about the fact that the addition of CABG to AVR slightly improves long-term survival, even in high-risk populations (19).
Delay in the management of patients with AS may give rise to certain “cardiac” profiles that are intrinsically associated with poor outcomes following AVR. Thus when hypertrophy fails to normalise wall stress, the abnormal afterload leads to reduced ventricular ejection, reducing cardiac output, adding to the heart failure syndrome (20). This subset of patients with low gradient AS and low EF is known to be associated with poorer outcomes after AVR. A poor outcome is seen in 5–10% of all cases of severe AS (21) and defined as patients with a mean gradient <30 mmHg (or 40 mm Hg), an aortic valve area <1 cm², and an EF<35% (or 40%). The associated myocardial dysfunction contributes to poor prognosis. Since the transvalvular gradient is small, there is a correspondingly smaller reduction in afterload and thus a smaller improvement in EF following surgery (22). AVR in this group of patients carries a poor prognosis with a reported operative mortality as high as 21% with a 50% death rate within 4 years of the procedure (23). Although AVR is superior to medical management in terms of short-term survival, surgery is not recommended to all low-gradient, low-EF patients. inotropic reserve as well as a large increase in aortic valve area with increased output generally considered a contraindication and patients with these are least likely to benefit from AVR . Nevertheless, in a recent international multicenter registry of low EF/low gradient AS, AVR was associated with superior survival and was advocated when mean pressure gradient was >20 mm Hg and in the absence of excessive comorbidities or severe CAD with large scarring which would be caused by extensive myocardial infarction (24).
In addition to comorbidities, patients may present with technical difficulties and complexities which make AVR challenging to perform. This is particularly true in patients undergoing redo surgery with patent coronary artery bypass grafts, where the risk of injury to the graft during dissection can be prejudicious to myocardial vascularisation. The matter is further complicated by issues related to cardioplegia when the patent grafts are the internal thoracic arteries. Patients with previous mediastinal radiotherapy and radiation damage to the myocardium are also known to have poor outcomes. Finally, in the presence of a heavily calcified and atheromatous ascending aorta (porcelain aorta), cross clamping and aortotomy may be impossible.
1. Chizner MA, Pearle DL, deLeon Jr AC. The natural history of aortic stenosis in adults Am Heart J 1980;99:419-424. 2. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease. The Task Force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230-268. 3. STS National Database. STS US Cardiac Surgery Database: 1997 Aortic Valve Replacement Patients: Preoperative Risk Variables. Chicago: Society of Thoracic Surgeons; 2000. 4. Mihaljevic T, Nowicki ER, Rajeswaran J, et al. Survival after valve replacement for aortic stenosis: implications for decision making. J Thorac Cardiovasc Surg. 2008;135:1270-8. 5. Nowicki ER, Birkmeyer NJ, Weintraub RW, et al; Northern New England Cardiovascular Disease Study Group and the Center for Evaluative Clinical Sciences, Dartmouth Medical School. Multivariable prediction of in-hospital mortality associated with aortic and mitral valve surgery in Northern New England. Ann Thorac Surg. 2004;77:1966-77. 6. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-1243. 7. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg 2006;82:2111-2115. 8. Hannan EL, Samadashvili Z, Lahey SJ, et al. Aortic Valve Replacement for Patients With Severe Aortic Stenosis: Risk Factors and Their Impact on 30-Month Mortality. Ann. Thorac. Surg. 2009;87:1741-1749. 9. Varadarajan P, Kapoor N, Bansal RC, et al. Survival in elderly patients with severe aortic stenosis is dramatically improved by aortic valve replacement: Results from a cohort of 277 patients aged > or =80 years. Eur J Cardiothorac Surg. 2006;30:722-7. 10. Asimakopoulos G, Edwards MB, Taylor KM. Aortic valve replacement in patients 80 years of age and older: survival and cause of death based on 1100 cases: collective results from the UK Heart Valve Registry. Circulation. 1997 18;96:3403-8. 11. Dewey TM, Brown D, Ryan WH, et al. Reliability of risk algorithms in predicting early and late operative outcomes in high risk patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg 2008;135:180-187 12. Alexander KP, Anstrom KJ, Muhlbaier LH, et al. Outcomes of cardiac surgery in patients age > 80 years: results from the National Cardiovascular Network. J Am Coll Cardiol 2000;35:731–8 13. Florath I, Rosendahl UP, Mortasawi A, et al. Current determinants of operative mortality in 1400 patients requiring aortic valve replacement. Ann Thorac Surg 2003;76:75– 83. 14. Bonow RO, Carabello B, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Valvular Heart Disease). Circulation 2006;114:e84 –231. 15. Edwards MB, Taylor KM. Outcomes in nonagenarians after heart valve replacement operation. Ann Thorac Surg 2003;75:830-834. 16. Florath I, Albert A, Rosendahl U, et al. Mid term outcome and quality of life after aortic valve replacement in elderly people: mechanical versus stentless biological valves. Heart. 2005;91:1023-9. 17. Bouma BJ, van Den Brink RB, Zwinderman K, et al. Which elderly patients with severe aortic stenosis benefit from surgical treatment? An aid to clinical decision making. J Heart Valve Disease 2004;13:374–81. 18. Iung B, Cachier A, Baron G, et al. Decision making in elderly patients with severe aortic stenosis : Why are so many denied surgery ? Eur Heart J 2005; 26: 2714-2720. 19. Kobayashi KJ, Williams JA, Nwakanma L, et al. Aortic Valve Replacement and Concomitant Coronary Artery Bypass: Assessing the Impact of Multiple Grafts. Ann Thorac Surg, 2007;83:969-978. 20. Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009 14;373:956-66. 21. Levy F, Laurent M, Monin JL, et al. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and long-term outcome: a European multicenter study. J Am Coll Cardiol 2008;51:1466–72. 22. Carabello BA. Is it ever too late to operate on the patient with valvular heart disease? J Am Coll Cardiol. 2004 21;44:376-83. 23. Connolly HM, Oh JK, Schaff HV, et al. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction: result of aortic valve replacement in 52 patients. Circulation 2000;101: 1940–6. 24. Tribouilloy C, Lévy F, Rusinaru D, et al. Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. J Am Coll Cardiol. 2009;53:1865-73.
Nawwar Al-Attar, FRCS, FETCS, PhD Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Cardiac Surgery, Bichat – Claude Bernard Hospital, Paris, France
© 2017 European Society of Cardiology. All rights reserved